• Shares of FMC Corporation (FMC) advanced 13.2% after the company agreed to buy E I Du Pont De Nemours And Co's (DD) crop protection business.
• BlackBerry Ltd’s (BBRY) shares advanced 11.5% after reporting a fiscal 2017 fourth quarter loss of $0.01 per share, which beat the Zacks Consensus Estimate of a loss of $0.04 per share
• Shares of Akari Therapeutics, Plc (AKTX) gained 58.1% after the FDA granted Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria (PNH)
• TRC Companies, Inc.’s (TRR) shares gained 46% after private equity firm New Mountain Capital decided to acquire the company
• Shares of FMC Corporation (FMC) advanced 13.2% after the company agreed to buy E I Du Pont De Nemours And Co's (DD) crop protection business.
• BlackBerry Ltd’s (BBRY) shares advanced 11.5% after reporting a fiscal 2017 fourth quarter loss of $0.01 per share, which beat the Zacks Consensus Estimate of a loss of $0.04 per share
• Shares of Akari Therapeutics, Plc (AKTX) gained 58.1% after the FDA granted Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria (PNH)
• TRC Companies, Inc.’s (TRR) shares gained 46% after private equity firm New Mountain Capital decided to acquire the company
• Shares of FMC Corporation (FMC) advanced 13.2% after the company agreed to buy E I Du Pont De Nemours And Co's (DD) crop protection business.
• BlackBerry Ltd’s (BBRY) shares advanced 11.5% after reporting a fiscal 2017 fourth quarter loss of $0.01 per share, which beat the Zacks Consensus Estimate of a loss of $0.04 per share
• Shares of Akari Therapeutics, Plc (AKTX) gained 58.1% after the FDA granted Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria (PNH)
• TRC Companies, Inc.’s (TRR) shares gained 46% after private equity firm New Mountain Capital decided to acquire the company
• Shares of FMC Corporation (FMC) advanced 13.2% after the company agreed to buy E I Du Pont De Nemours And Co's (DD) crop protection business.
• BlackBerry Ltd’s (BBRY) shares advanced 11.5% after reporting a fiscal 2017 fourth quarter loss of $0.01 per share, which beat the Zacks Consensus Estimate of a loss of $0.04 per share
• Shares of Akari Therapeutics, Plc (AKTX) gained 58.1% after the FDA granted Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria (PNH)
• TRC Companies, Inc.’s (TRR) shares gained 46% after private equity firm New Mountain Capital decided to acquire the company
- Shares of FMC Corporation FMC advanced 13.2% after the company agreed to buy E I Du Pont De Nemours And Co's DD crop protection business.
- BlackBerry Ltd’s BBRY shares advanced 11.5% after reporting a fiscal 2017 fourth quarter loss of $0.01 per share, which beat the Zacks Consensus Estimate of a loss of $0.04 per share
- Shares of Akari Therapeutics, Plc AKTX gained 58.1% after the FDA granted Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria (PNH)
- TRC Companies, Inc.’s TRR shares gained 46% after private equity firm New Mountain Capital decided to acquire the company
• Shares of FMC Corporation (FMC) advanced 13.2% after the company agreed to buy E I Du Pont De Nemours And Co's (DD) crop protection business.
• BlackBerry Ltd’s (BBRY) shares advanced 11.5% after reporting a fiscal 2017 fourth quarter loss of $0.01 per share, which beat the Zacks Consensus Estimate of a loss of $0.04 per share
• Shares of Akari Therapeutics, Plc (AKTX) gained 58.1% after the FDA granted Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria (PNH)
• TRC Companies, Inc.’s (TRR) shares gained 46% after private equity firm New Mountain Capital decided to acquire the compan
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
E.I. du Pont de Nemours and Company (DD): Free Stock Analysis Report
FMC Corporation (FMC): Free Stock Analysis Report
BlackBerry Limited (BBRY): Free Stock Analysis Report
Akari Therapeutics PLC (AKTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
April 03, 2017 at 08:24PM
http://ift.tt/2nSHXig
from Zacks Equity Research
http://ift.tt/2nSHXig
No comments:
Post a Comment